KR102683355B1 - 조합하여 사용되는 항진균제 - Google Patents

조합하여 사용되는 항진균제 Download PDF

Info

Publication number
KR102683355B1
KR102683355B1 KR1020197032870A KR20197032870A KR102683355B1 KR 102683355 B1 KR102683355 B1 KR 102683355B1 KR 1020197032870 A KR1020197032870 A KR 1020197032870A KR 20197032870 A KR20197032870 A KR 20197032870A KR 102683355 B1 KR102683355 B1 KR 102683355B1
Authority
KR
South Korea
Prior art keywords
therapeutic agent
combination
delete delete
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197032870A
Other languages
English (en)
Korean (ko)
Other versions
KR20190133251A (ko
Inventor
데이비드 에이. 안굴로 곤잘레스
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Priority to KR1020247022473A priority Critical patent/KR103003856B1/ko
Publication of KR20190133251A publication Critical patent/KR20190133251A/ko
Application granted granted Critical
Publication of KR102683355B1 publication Critical patent/KR102683355B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020197032870A 2017-04-10 2018-04-04 조합하여 사용되는 항진균제 Active KR102683355B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247022473A KR103003856B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10
US62/483,647 2017-04-10
PCT/US2018/026088 WO2018191077A1 (en) 2017-04-10 2018-04-04 Antifungal agents used in combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022473A Division KR103003856B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제

Publications (2)

Publication Number Publication Date
KR20190133251A KR20190133251A (ko) 2019-12-02
KR102683355B1 true KR102683355B1 (ko) 2024-07-10

Family

ID=62063223

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032870A Active KR102683355B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제

Country Status (13)

Country Link
US (2) US11110102B2 (cg-RX-API-DMAC7.html)
EP (1) EP3609539A1 (cg-RX-API-DMAC7.html)
JP (2) JP7263313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102683355B1 (cg-RX-API-DMAC7.html)
CN (1) CN110769854B (cg-RX-API-DMAC7.html)
AR (1) AR113221A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018253031B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059225A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992413A1 (cg-RX-API-DMAC7.html)
MA (1) MA49889A (cg-RX-API-DMAC7.html)
MX (1) MX2019012116A (cg-RX-API-DMAC7.html)
TW (1) TWI806861B (cg-RX-API-DMAC7.html)
WO (1) WO2018191077A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3661503T3 (pl) * 2017-08-04 2023-01-09 Scynexis, Inc. Środki przeciwgrzybicze o zwiększonej aktywności przy kwasowym odczynie ph
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PL3221308T3 (pl) * 2014-11-21 2019-03-29 F2G Limited Środki przeciwgrzybicze
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antimicrobial agents and chemotherapy, 2013, 57(10), 4656-4663*

Also Published As

Publication number Publication date
JP7263313B2 (ja) 2023-04-24
WO2018191077A1 (en) 2018-10-18
AR113221A1 (es) 2020-02-19
EP3609539A1 (en) 2020-02-19
CN110769854A (zh) 2020-02-07
CN110769854B (zh) 2023-01-13
TW201842915A (zh) 2018-12-16
KR20190133251A (ko) 2019-12-02
US20180325919A1 (en) 2018-11-15
US20220202833A1 (en) 2022-06-30
JP2023030113A (ja) 2023-03-07
AU2018253031B2 (en) 2024-04-11
MX2019012116A (es) 2019-11-21
AU2018253031A1 (en) 2019-10-31
KR20240110109A (ko) 2024-07-12
BR112019021138A2 (pt) 2020-05-12
EA201992413A1 (ru) 2020-03-16
MA49889A (fr) 2020-06-24
TWI806861B (zh) 2023-07-01
JP2020513037A (ja) 2020-04-30
JP7574268B2 (ja) 2024-10-28
CA3059225A1 (en) 2018-10-18
US11110102B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
JP7574268B2 (ja) 併用される抗真菌剤
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
BRPI0912074B1 (pt) Composto e composição farmacêutica
EP3917534B1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40022879B (en) Antifungal agents used in combination
HK40022879A (en) Antifungal agents used in combination
BR112019021138B1 (pt) Combinação farmacêutica, e, uso de uma combinação farmacêutica
EA047299B1 (ru) Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601